Experience in vein shaping by perivenous fluids led to the invention and first presentations of percutaneous valvuloplasty (PVP) by ultrasound-monitored perivenous injection in 2013. Meanwhile, ultrasound criteria have been improved, a simple test by perivenous saline injection has been established, and two pilot series with different cross-linked hyaluronan gels have been completed including a 1-year follow-up. Now, a comparison of those two studies is presented. Patients with proximal great saphenous vein valve incompetence but preserved and mobile valve structures according to 8 to 16 MHz ultrasound analysis were included. In series A, 23 patients (15 women, 8 men; 38-67 years; diameter, 7.0-11.5 mm [mean, 8.6 mm]) underwent PVP with hyaluronan gel consisting of large particles (>1 mm, Macrolane; Q-Med, Surrey, UK). In series B, a smooth hyaluronan gel (particles <0.2 mm, prototype approved for aesthetic use) was chosen for 18 patients (12 women, 6 men; 34-69 years; great saphenous vein diameter, 7.0-11.8 mm [mean, 8.9 mm]; Fig 1). Orthograde flow was established in 22 of 23 cases in series A (95.6%) and 18 of 18 cases in series B (100%; Fig 2). Gel volumes were 12 to 35 mL (mean, 19.4 mL, A) vs 4 to 9 mL (mean, 6.9 mL, B). There were no adverse reactions. At 1-year follow-up, orthograde flow was present in 15 of 22 cases (68.2%, A) vs 14 of 18 cases (78.6%, B). Cases with recurring reflux successfully received supplementary hyaluronan injections of 2 to 6 mL. At 1-year follow-up, the assisted success rate was 97.6%. Both substances decreased with time, but correlation with the vein diameter was not clear. Meanwhile, 5 of 11 initial cases with >2 years of follow-up still showed orthograde flow without additional injection, but hyaluronan was no longer able to be depicted. PVP is the first minimally invasive method to eliminate venous reflux while fully preserving the target vein. It is successfully feasible as well with large-particle hyaluronan as with smoother gels. Small-particle gels may be placed more precisely but are much more expensive when designed to be long-lasting. Efforts are now on the manufacturers to provide a definite substance for PVP approval.Fig 2Incompetent GSV, pre and post valvuloplasty.View Large Image Figure ViewerDownload Hi-res image Download (PPT)
Read full abstract